DZ2026A1 - Compositions vaccinantes. - Google Patents

Compositions vaccinantes.

Info

Publication number
DZ2026A1
DZ2026A1 DZ960068A DZ960068A DZ2026A1 DZ 2026 A1 DZ2026 A1 DZ 2026A1 DZ 960068 A DZ960068 A DZ 960068A DZ 960068 A DZ960068 A DZ 960068A DZ 2026 A1 DZ2026 A1 DZ 2026A1
Authority
DZ
Algeria
Prior art keywords
vaccinating compositions
vaccinating
compositions
Prior art date
Application number
DZ960068A
Other languages
English (en)
Inventor
Nathalie Marie
Josephe Claude Garcon
Martin Friede
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306923&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DZ2026(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9508326.7A external-priority patent/GB9508326D0/en
Priority claimed from GBGB9513107.4A external-priority patent/GB9513107D0/en
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Application granted granted Critical
Publication of DZ2026A1 publication Critical patent/DZ2026A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
DZ960068A 1995-04-25 1996-04-24 Compositions vaccinantes. DZ2026A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9508326.7A GB9508326D0 (en) 1995-04-25 1995-04-25 Vaccines
GBGB9513107.4A GB9513107D0 (en) 1995-06-28 1995-06-28 Vaccines

Publications (1)

Publication Number Publication Date
DZ2026A1 true DZ2026A1 (fr) 2002-07-21

Family

ID=26306923

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ960068A DZ2026A1 (fr) 1995-04-25 1996-04-24 Compositions vaccinantes.

Country Status (37)

Country Link
EP (3) EP0822831B2 (fr)
JP (1) JP3901731B2 (fr)
KR (1) KR100463372B1 (fr)
CN (3) CN1289065C (fr)
AP (1) AP771A (fr)
AR (1) AR001686A1 (fr)
AT (2) ATE373487T1 (fr)
AU (2) AU693022B2 (fr)
BG (1) BG63491B1 (fr)
BR (1) BR9608199B1 (fr)
CA (1) CA2217178C (fr)
CY (1) CY2588B2 (fr)
CZ (1) CZ296216B6 (fr)
DE (2) DE69605296T3 (fr)
DK (2) DK0955059T3 (fr)
DZ (1) DZ2026A1 (fr)
EA (1) EA000839B1 (fr)
ES (2) ES2140076T5 (fr)
GR (1) GR3031912T3 (fr)
HK (2) HK1009086A1 (fr)
HU (1) HU227944B1 (fr)
IL (1) IL118004A (fr)
MA (1) MA23850A1 (fr)
MY (1) MY134811A (fr)
NO (1) NO322190B1 (fr)
NZ (1) NZ305365A (fr)
OA (1) OA10629A (fr)
PL (1) PL184061B1 (fr)
PT (1) PT955059E (fr)
RO (1) RO119068B1 (fr)
SA (1) SA96170297B1 (fr)
SI (2) SI0822831T2 (fr)
SK (1) SK282017B6 (fr)
TR (1) TR199701252T1 (fr)
TW (1) TW515715B (fr)
UA (1) UA56132C2 (fr)
WO (1) WO1996033739A1 (fr)

Families Citing this family (488)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
GB9620795D0 (en) * 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AUPO732997A0 (en) * 1997-06-12 1997-07-03 Csl Limited Ganglioside immunostimulating complexes and uses thereof
US6645495B1 (en) * 1997-08-29 2003-11-11 Antigenics, Inc. Compositions of saponin adjuvants and excipients
DE69838992T2 (de) * 1997-09-05 2008-12-24 Glaxosmithkline Biologicals S.A., Rixensart Öl-in-Wasser Emulsionen mit Saponinen
GB9718901D0 (en) * 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
GB9724531D0 (en) 1997-11-19 1998-01-21 Smithkline Biolog Novel compounds
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
DK1659178T3 (da) 1998-02-05 2010-07-12 Glaxosmithkline Biolog Sa Fremgangsmåde til oprensning eller fremstilling af et MAGE-protein
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
KR100692227B1 (ko) 1998-04-07 2007-03-09 코릭사 코포레이션 마이코박테리움 튜베르쿨로시스 항원의 융합 단백질 및이의 용도
GB9808866D0 (en) 1998-04-24 1998-06-24 Smithkline Beecham Biolog Novel compounds
GB9817052D0 (en) * 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
BR9912671A (pt) 1998-08-07 2001-05-02 Univ Washington Antìgenos imunológicos para o vìrus de herpes simples e métodos para sua utilização
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
DE69935606T9 (de) 1998-10-16 2021-03-11 Glaxosmithkline Biologicals S.A. Adjuvanzsysteme und impfstoffe
CA2354028A1 (fr) 1998-12-08 2000-06-15 Smithkline Beecham Biologicals S.A. Polypeptides basb041 de neisseria meningitidis et polynucleotides codant ces polypeptides, et leurs utilisations
IL143531A0 (en) 1998-12-08 2002-04-21 Corixa Corp Polypeptides containing an antigenic portion of a chlamydia antigen, dna sequences encoding said polypeptides and pharmaceutical compositions and vaccines containing the same
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US7776343B1 (en) 1999-02-17 2010-08-17 Csl Limited Immunogenic complexes and methods relating thereto
US8221761B1 (en) * 1999-02-26 2012-07-17 Novartis Ag Enhancement of bactericidal activity of neisseria antigens with oligonucleotides containing CG motifs
EP1163343B1 (fr) 1999-03-12 2009-12-09 GlaxoSmithKline Biologicals S.A. Polypeptides antigeniques de neisseria meningitidis, et polynucleotides et anticorps protecteurs correspondant
GB9909077D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
CZ303653B6 (cs) * 1999-03-19 2013-01-30 Smithkline Beecham Biologicals S. A. Imunogenní prostredek
ES2308976T3 (es) 1999-04-02 2008-12-16 Corixa Corporation Compuestos y metodos para la terapia y el diagnostico del cancer de pulmon.
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
WO2000062800A2 (fr) * 1999-04-19 2000-10-26 Smithkline Beecham Biologicals Sa Vaccins
GB9908885D0 (en) * 1999-04-19 1999-06-16 Smithkline Beecham Biolog Vccine
US7166573B1 (en) 1999-05-28 2007-01-23 Ludwig Institute For Cancer Research Breast, gastric and prostate cancer associated antigens and uses therefor
US6432411B1 (en) * 1999-07-13 2002-08-13 Hawaii Biotechnology Group Recombinant envelope vaccine against flavivirus infection
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
AU1013701A (en) 1999-10-22 2001-05-08 Aventis Pasteur Limited Modified gp100 and uses thereof
US6905712B2 (en) 1999-12-08 2005-06-14 Statens Veterinarmedicinska Anstalt Vaccine adjuvants comprising ginseng plant extract and added aluminum salt
EP1235591A1 (fr) * 1999-12-08 2002-09-04 Statens Veterinärmedicinska Anstalt Adjuvants de vaccins comportant de l'extrait vegetal de ginseng et un sel d'aluminium
CA2400842C (fr) 2000-02-23 2013-01-15 Smithkline Beecham Biologicals S.A. Nouveaux composes
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
EP1385541B1 (fr) * 2000-04-13 2008-06-18 Corixa Corporation Compositions immunostimulantes comprenant un phosphate d'aminoalkyl glucosaminide et du qs-21
EP1278855B1 (fr) 2000-04-21 2008-03-12 Corixa Corporation Composes et procedes pour le traitement et le diagnostic d'une infection de chlamydia
AU5810201A (en) 2000-05-10 2001-11-20 Aventis Pasteur Immunogenic polypeptides encoded by mage minigenes and uses thereof
CA2413959C (fr) 2000-06-20 2015-07-07 Corixa Corporation Proteines de fusion du mycobacterium tuberculosis
WO2002000174A2 (fr) 2000-06-28 2002-01-03 Corixa Corporation Compositions et methodes pour le traitement et le diagnostic du cancer du poumon
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
PT1296715E (pt) 2000-06-29 2012-01-19 Smithkline Beecham Biolog Composição vacinal multivalente
UA79735C2 (uk) 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
US6858590B2 (en) 2000-08-17 2005-02-22 Tripep Ab Vaccines containing ribavirin and methods of use thereof
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
ES2295229T3 (es) * 2000-10-18 2008-04-16 Glaxosmithkline Biologicals S.A. Vacunas contra canceres.
EP2266603B1 (fr) 2000-10-18 2012-09-12 GlaxoSmithKline Biologicals S.A. Vaccins contre le cancer
EP1201250A1 (fr) * 2000-10-25 2002-05-02 SMITHKLINE BEECHAM BIOLOGICALS s.a. Composition immunogène contenant des antigènes de plasmodium spécifiques des stades hépatiques
US7306806B2 (en) 2001-01-26 2007-12-11 United States Of America As Represented By The Secretary Of The Army Recombinant P. falciparum merozoite protein-142 vaccine
EP1423421A2 (fr) * 2001-01-26 2004-06-02 Walter Reed Army Institute of Research Isolation et purification and purification de vaccin a base de proteine-1 42 merozoite de p. falciparum
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
PT1361890E (pt) * 2001-02-23 2011-06-07 Glaxosmithkline Biolog Sa Formulações vacinais de influenza para distribuição intradérmica
EP1361889A1 (fr) * 2001-02-23 2003-11-19 GlaxoSmithKline Biologicals S.A. Nouveau vaccin
US20030031684A1 (en) 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
US7713942B2 (en) * 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
EP1988097A1 (fr) 2001-05-09 2008-11-05 Corixa Corporation Compositions et procédés pour le traitement et le diagnostic du cancer de la prostate
US20100221284A1 (en) 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
NZ530315A (en) 2001-07-10 2007-01-26 Corixa Corp Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
GB0118367D0 (en) 2001-07-27 2001-09-19 Glaxosmithkline Biolog Sa Novel use
WO2003010194A2 (fr) 2001-07-27 2003-02-06 Chiron Srl. Adhesines des meningocoques
US20030138434A1 (en) * 2001-08-13 2003-07-24 Campbell Robert L. Agents for enhancing the immune response
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
GB0123580D0 (en) * 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
WO2003053220A2 (fr) 2001-12-17 2003-07-03 Corixa Corporation Compositions et procedes applicables a la therapie et au diagnostic pour la maladie intestinale inflammatoire
US7351413B2 (en) 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
DE10211088A1 (de) 2002-03-13 2003-09-25 Ugur Sahin Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US6861410B1 (en) 2002-03-21 2005-03-01 Chiron Corporation Immunological adjuvant compositions
PL209696B1 (pl) 2002-04-19 2011-10-31 Univ Toronto Peptyd, kompozycja peptydowa, kompozycja immunogenna, zastosowania kompozycji immunogennej oraz sposób określania czy związek stanowi inhbitor odkładania się i tworzenia włókienek amyloidu
DE60324678D1 (de) 2002-07-18 2008-12-24 Univ Washington N t-lymphozyten und damit identifizierte hsv-antigene
KR101239242B1 (ko) 2002-08-02 2013-03-11 글락소스미스클라인 바이오로지칼즈 에스.에이. 항원 조합물을 포함하는 나이세리아 백신 조성물
WO2004032958A1 (fr) 2002-10-11 2004-04-22 Chiron Srl Vaccins polypeptidiques offrant une large protection contre des lignees de meningocoques hypervirulentes
NZ539509A (en) 2002-10-23 2008-05-30 Glaxosmithkline Biolog Sa Priming vaccine comprising a polynucleotide encoding at least one first malarial antigen and a boosting vaccine comprising at least one polypeptide comprising at least one second malarial antigen having at least one epitope in common with the first malarial antigen of the priming vaccine
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
CA2511907A1 (fr) 2003-01-06 2004-07-22 Wyeth Compositions et procede permettant de diagnostiquer et de traiter les cancers du colon
US20050089533A1 (en) * 2003-01-29 2005-04-28 Joseph Frantz Canine vaccines against Bordetella bronchiseptica
CA2513352C (fr) 2003-01-29 2010-10-12 Pfizer Products Inc. Vaccins canins contre la bordetella bronchiseptica
WO2004067030A2 (fr) 2003-01-30 2004-08-12 Chiron Srl Vaccins injectables contre les multiples serogroupes du meningocoque
WO2004087204A2 (fr) 2003-04-04 2004-10-14 Pfizer Products Inc. Emulsions microfluidifiees d'huile dans l'eau et compositions de vaccins
US7879338B2 (en) 2003-07-21 2011-02-01 Boyce Thompson Institute For Plant Research Vectors and methods for immunization against norovirus using transgenic plants
EP1648500B1 (fr) 2003-07-31 2014-07-09 Novartis Vaccines and Diagnostics, Inc. Compositions immunogenes pour streptoccus pyogenes
DE10341812A1 (de) 2003-09-10 2005-04-07 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE10344799A1 (de) 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
WO2005032584A2 (fr) 2003-10-02 2005-04-14 Glaxosmithkline Biologicals S.A. Composes
ATE506963T1 (de) 2003-10-02 2011-05-15 Novartis Vaccines & Diagnostic Kombinationsimpfstoffe gegen meningitis
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
AU2004308964B2 (en) 2003-12-23 2010-09-16 Arbor Vita Corporation Antibodies for oncogenic strains of HPV and methods of their use
ES2617062T3 (es) 2004-02-05 2017-06-15 The Ohio State University Research Foundation Péptidos VEGF quiméricos
US7767792B2 (en) 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
JP5600375B2 (ja) 2004-03-09 2014-10-01 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド インフルエンザウイルスワクチン
KR20070008625A (ko) * 2004-04-05 2007-01-17 화이자 프로덕츠 인코포레이티드 미세유체화된 수중유 유화액 및 백신 조성물
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
BRPI0510315A (pt) 2004-04-30 2007-10-16 Chiron Srl integração de vacinação com conjugado meningocócico
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
DE102004023187A1 (de) 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP2811027A1 (fr) 2004-05-21 2014-12-10 Novartis Vaccines and Diagnostics, Inc. Vecteurs alphavirus pour vaccins contre le VRS et le PIV
AU2005285513B2 (en) 2004-05-25 2011-02-24 Oregon Health And Science University SIV and HIV vaccination using RhCMV- and HCMV-based vaccine vectors
AU2005249212B2 (en) 2004-05-28 2010-05-20 Glaxosmithkline Biologicals S.A. Vaccine compositions comprising virosomes and a saponin adjuvant
EP2612679A1 (fr) 2004-07-29 2013-07-10 Novartis Vaccines and Diagnostics, Inc. Compositions immunogènes pour une bactérie à gram positif telle que streptococcus agalactiae
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
GB0420634D0 (en) * 2004-09-16 2004-10-20 Glaxosmithkline Biolog Sa Vaccines
EP2305294B1 (fr) 2004-09-22 2015-04-01 GlaxoSmithKline Biologicals SA Composition immunogène pour la vaccination contre des staphylocoques
DK3312272T3 (da) 2004-10-08 2019-12-02 Us Gov Health & Human Services Modulering af replikationstilpasning ved brug a mindre optrædende synonyme kodoner
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
EP1835027B1 (fr) 2004-12-07 2015-02-25 Toray Industries, Inc. Nouveau peptide antigène contre le cancer et applications
WO2006066089A1 (fr) 2004-12-15 2006-06-22 Neuralab Limited Anticorps du peptide beta-amyloide humanises utilises dans l'amelioration de la cognition
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
CN101203529A (zh) 2005-02-18 2008-06-18 诺华疫苗和诊断公司 来自脑膜炎/脓毒症相关性大肠杆菌的蛋白质和核酸
SI2351772T1 (sl) 2005-02-18 2016-11-30 Glaxosmithkline Biologicals Sa Proteini in nukleinske kisline iz Escherichia coli povezane z meningitisom/sepso
GB0504436D0 (en) 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
JP5869744B2 (ja) 2005-03-23 2016-02-24 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｃｄ４ｔ細胞および／または改善された記憶ｂ細胞応答を誘導するためのインフルエンザウイルスおよび水中油型エマルジョンアジュバントの使用
DE102005013846A1 (de) 2005-03-24 2006-10-05 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
US8541007B2 (en) 2005-03-31 2013-09-24 Glaxosmithkline Biologicals S.A. Vaccines against chlamydial infection
EP2392349A3 (fr) 2005-03-31 2012-01-18 GlaxoSmithKline Biologicals S.A. Vaccins contre l'infection à chlamydia
ES2381492T3 (es) 2005-04-29 2012-05-28 Glaxosmithkline Biologicals Sa Procedimiento de prevención o tratamiento de infección por M. tuberculosis
WO2006138675A2 (fr) 2005-06-15 2006-12-28 The Ohio State University Research Foundation Peptides her-2
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
ATE530569T1 (de) 2005-07-01 2011-11-15 Forsyth Dental In Ry For Children Fa Assays zum nachweis von tuberkulose- antigenen, und impfstoffe
EP1762575A1 (fr) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification d' antigènes associés aux tumeurs pour diagnose et thérapie
GB0519871D0 (en) 2005-09-30 2005-11-09 Secr Defence Immunogenic agents
EP2357000A1 (fr) 2005-10-18 2011-08-17 Novartis Vaccines and Diagnostics, Inc. Immunisations mucosiques et systémiques avec des particules de réplicon à alpha-virus
NZ567817A (en) 2005-11-01 2012-01-12 Novartis Vaccines & Diagnostic Cell-derived viral vaccines with low levels of residual cell DNA by beta-propiolactone treatment
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
CA2628152C (fr) 2005-11-04 2016-02-02 Novartis Vaccines And Diagnostics S.R.L. Vaccins avec adjuvant comprenant des antigenes sans virions prepares a partir de virus influenza eleves en culture cellulaire
WO2007081447A2 (fr) 2005-11-22 2007-07-19 Novartis Vaccines And Diagnostics, Inc. Antigènes de norovirus et de sapovirus
EP1790664A1 (fr) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Anticorps monoclonaux contre claudin-18 pour le traitement du cancer
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
DE102005059242A1 (de) 2005-12-12 2007-06-14 Johannes Gutenberg-Universität Mainz, Vertreten Durch Den Präsidenten Molekulare Marker für eine Tumordiagnose und -therapie
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
CA2808919C (fr) 2005-12-22 2016-04-19 Glaxosmithkline Biologicals S.A. Vaccin comportant des conjugues polysaccharides capsulaires streptococcus pneumoniae
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
WO2007082105A2 (fr) 2006-01-16 2007-07-19 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Vaccin contre chlamydia
BRPI0707154B8 (pt) 2006-01-17 2022-12-20 Forsgren Arne composição de vacina
DK1976559T6 (da) 2006-01-27 2020-04-06 Seqirus Uk Ltd Influenzavacciner indeholdende hæmagglutinin og matrixproteiner
ES2536426T3 (es) 2006-03-23 2015-05-25 Novartis Ag Compuestos de imidazoquinoxalina como inmunomoduladores
EP2004226A1 (fr) 2006-03-24 2008-12-24 Novartis Vaccines and Diagnostics GmbH & Co. KG Stockage de vaccins antigrippaux sans refrigeration
PL2004220T3 (pl) 2006-03-30 2015-11-30 Zoetis Services Llc Sposoby i kompozycje do szczepienia drobiu
EP2476434A1 (fr) 2006-03-30 2012-07-18 GlaxoSmithKline Biologicals S.A. Composition immunogène
EP2382988A1 (fr) 2006-03-31 2011-11-02 Novartis AG Immunisation mucosique et parentérale contre le VIH
US10138279B2 (en) 2006-04-13 2018-11-27 Regents Of The University Of Michigan Compositions and methods for Bacillus anthracis vaccination
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
WO2009017467A1 (fr) 2007-07-27 2009-02-05 Elan Pharma International Limited Traitement de maladies amyloïdogéniques
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AR061136A1 (es) 2006-06-02 2008-08-06 Glaxosmithkline Biolog Sa Procedimiento
US20110206692A1 (en) 2006-06-09 2011-08-25 Novartis Ag Conformers of bacterial adhesins
JP5275983B2 (ja) 2006-06-12 2013-08-28 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
CN101479293A (zh) 2006-06-29 2009-07-08 诺华有限公司 脑膜炎奈瑟球菌多肽
PL2422810T3 (pl) 2006-07-17 2015-03-31 Glaxosmithkline Biologicals Sa Szczepionka przeciw grypie
BRPI0715581A2 (pt) 2006-07-18 2013-04-24 Glaxosmithkline Biolog Sa proteÍna de fusço hÍbrida imunogÊnica, composiÇço, uso de uma proteÍna ou uma partÍcula, mÉtodo para tratar um paciente suscetÍvel À infecÇço por plasmàdio, sequÊncia de nucleotÍdeo, hospedeiro, e, processo para a produÇço de proteÍna
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
WO2008012538A2 (fr) 2006-07-25 2008-01-31 The Secretary Of State For Defence Souche de vaccin vivant
JP2010500399A (ja) 2006-08-16 2010-01-07 ノバルティス アーゲー 尿路病原性大腸菌由来の免疫原
AU2007293673B2 (en) 2006-09-07 2013-06-27 Glaxosmithkline Biologicals S.A. Vaccine
CA2663196A1 (fr) 2006-09-11 2008-03-20 Novartis Ag Fabrication de vaccins contre le virus grippal sans utiliser d'oeufs
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
EP2468300B1 (fr) 2006-09-26 2017-12-20 Infectious Disease Research Institute Composition de vaccin contenant un adjuvant synthétique
CN101522218B (zh) 2006-10-12 2012-09-26 葛兰素史密丝克莱恩生物有限公司 包含水包油乳液佐剂的疫苗
EP2086582B1 (fr) 2006-10-12 2012-11-14 GlaxoSmithKline Biologicals s.a. Vaccin comprenant une emulsion adjuvante huile en l'eau
ES2630205T3 (es) * 2006-11-20 2017-08-18 Duecom Uso de partículas que contengan lípidos que comprenden saponínas quillaja para el tratamiento del cáncer
NZ577405A (en) 2006-12-06 2012-08-31 Novartis Ag Vaccines including antigen from four strains of influenza virus
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
DK2137210T3 (en) 2007-03-02 2017-01-30 Glaxosmithkline Biologicals Sa Hitherto unknown method and compositions
DK2136836T3 (en) 2007-04-04 2017-04-10 Infectious Disease Res Inst Immunogenic compositions with mycobacterium tuberculosis polypeptides and fusions thereof
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
TW200908994A (en) 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
US20100322949A1 (en) 2007-04-26 2010-12-23 Ludwig Institute For Cancer Research Ltd. Methods for diagnosing and treating astrocytomas
EP2142211A1 (fr) 2007-05-02 2010-01-13 GlaxoSmithKline Biologicals S.A. Vaccin
EP2167531B1 (fr) 2007-05-25 2012-03-21 Novartis AG Antigènes de pilus de streptococcus pneumoniae
GB0711858D0 (en) * 2007-06-19 2007-07-25 Glaxosmithkline Biolog Sa Vaccine
EP2687228B1 (fr) 2007-06-26 2017-07-19 GlaxoSmithKline Biologicals S.A. Vaccin contenant des conjugues de polysaccharide capsulaire de streptococcus pneumoniae
EA201070066A1 (ru) 2007-06-27 2010-06-30 Новартис Аг Вакцины против гриппа с низким содержанием добавок
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
MX2010001284A (es) 2007-08-02 2010-08-31 Biondvax Pharmaceuticals Ltd Vacunas contra la influenza con multiepitope multimerico.
CA2695421A1 (fr) 2007-08-03 2009-02-12 President And Fellows Of Harvard College Antigenes chlamydiens
KR20100068390A (ko) 2007-08-13 2010-06-23 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
EP2185195A2 (fr) 2007-08-16 2010-05-19 Tripep Ab Plate-forme immunogène
KR101621837B1 (ko) 2007-09-12 2016-05-17 노파르티스 아게 Ｇａｓ57 돌연변이 항원 및 ｇａｓ57 항체
CN101932723B (zh) 2007-09-17 2014-09-10 肿瘤甲基化科学公司 改进的对mage-a表达的检测
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2060583A1 (fr) 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification des marqueurs associés aux tumeurs pour diagnostic et thérapie
ES2660414T3 (es) 2007-10-25 2018-03-22 Toray Industries, Inc. Inductor de la respuesta inmunitaria
EP2062594A1 (fr) 2007-11-21 2009-05-27 Wyeth Farma, S.A. Vaccin de la fièvre catarrhale du mouton et compositions immunogènes, procédé d'utilisation et son procédé de production
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
AU2008331800A1 (en) 2007-12-03 2009-06-11 President And Fellows Of Harvard College Chlamydia antigens
ES2626634T3 (es) 2007-12-19 2017-07-25 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Formas solubles de la glucoproteína F del virus de Hendra y Nipah y usos de la misma
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
CN104292312A (zh) 2007-12-21 2015-01-21 诺华股份有限公司 链球菌溶血素o的突变形式
AU2008340949A1 (en) 2007-12-24 2009-07-02 Glaxosmithkline Biologicals S.A. Recombinant RSV antigens
NZ587382A (en) 2008-02-21 2012-01-12 Novartis Ag Meningococcal fhbp polypeptides
EP2268309B1 (fr) 2008-03-18 2015-01-21 Novartis AG Améliorations dans la préparation des antigènes pour le vaccin contre le virus de la grippe
KR20110009157A (ko) 2008-04-16 2011-01-27 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
EP3329931B1 (fr) 2008-04-18 2022-06-08 The General Hospital Corporation Immunothérapies utilisant des vaccins autoassemblés
WO2009131673A1 (fr) 2008-04-25 2009-10-29 Ludwig Institute For Cancer Research Ltd. Traitement ciblé pour des sujets avec des cancers du sein négatifs au récepteur de l'œstrogène et négatifs au récepteur de la progestérone
US9415006B2 (en) 2008-05-23 2016-08-16 The Regents Of The University Of Michigan Immunogenic compositions comprising nanoemulsion and hepatitis B virus immunogen and methods of using the same
EP2318044B1 (fr) 2008-08-01 2015-12-02 Gamma Vaccines Pty Limited Vaccins contre la grippe
AU2009278385B2 (en) 2008-08-05 2015-06-11 Toray Industries, Inc. Immunity-inducing agent
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
WO2010036938A2 (fr) 2008-09-26 2010-04-01 Nanobio Corporation Compositions thérapeutiques de nanoémulsion et procédés d'utilisation de celles-ci
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
CA2743904A1 (fr) 2008-11-17 2010-05-20 The Regents Of The University Of Michigan Compositions de vaccins contre le cancer et leurs methodes d'utilisation
EP2356225A1 (fr) 2008-12-03 2011-08-17 Protea Vaccine Technologies Ltd. Fragments de glutamyl-arnt-synthétase (gts)
US8585505B2 (en) 2008-12-15 2013-11-19 Tetris Online, Inc. Inter-game interactive hybrid asynchronous computer game infrastructure
AU2010204139A1 (en) 2009-01-12 2011-08-11 Novartis Ag Cna_B domain antigens in vaccines against gram positive bacteria
GB0900455D0 (en) 2009-01-13 2009-02-11 Secr Defence Vaccine
GB0901423D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0901411D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
US20100234283A1 (en) 2009-02-04 2010-09-16 The Ohio State University Research Foundation Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
DK2396032T3 (en) 2009-02-10 2016-12-19 Seqirus Uk Ltd Influenza vaccines with reduced amounts of squalene
AR075437A1 (es) 2009-02-17 2011-03-30 Glaxosmithkline Biolog Sa Composicion inmunogenica que comprende al menos un antigeno del virus del dengue inactivado y un adyuvante sin aluminio, metodo para producir dicha vacuna y su uso para preparar un medicamento
EP2221375A1 (fr) 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Procédé et compositions pour le diagnostic et le traitement du cancer
EP2221063A1 (fr) 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Procédé et compositions pour le diagnostic et le traitement du cancer
KR20110128316A (ko) 2009-02-20 2011-11-29 가니메드 파마슈티칼스 아게 암의 진단 및 치료를 위한 방법 및 조성물
US8568732B2 (en) 2009-03-06 2013-10-29 Novartis Ag Chlamydia antigens
KR20120002534A (ko) 2009-03-17 2012-01-05 엠디엑스헬스 에스에이 유전자 발현의 향상된 검출
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
PL2510947T3 (pl) 2009-04-14 2016-09-30 Kompozycje do immunizacji przeciwko Staphylococcus aureus
EP2249159A1 (fr) 2009-04-29 2010-11-10 Ganymed Pharmaceuticals AG Identification des marqueurs associés aux tumeurs pour diagnostic et thérapie
WO2010132833A1 (fr) 2009-05-14 2010-11-18 The Regents Of The University Of Michigan Compositions vaccinales contre streptococcus et méthodes d'utilisation associées
CN102481312B (zh) 2009-06-05 2015-07-15 传染性疾病研究院 合成的吡喃葡萄糖脂佐剂
GB0910046D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
GB0910045D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
EP2442826B1 (fr) 2009-06-15 2015-07-08 National University of Singapore Vaccin contre l'influenza, composition, et procedes d'utilisation
JP6110140B2 (ja) 2009-06-16 2017-04-05 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン ナノエマルションワクチン
US9492531B2 (en) 2009-06-24 2016-11-15 Glaxosmithkline Biologicals Sa Recombinant RSV vaccines
MX2012000036A (es) 2009-06-24 2012-02-28 Glaxosmithkline Biolog Sa Vacuna.
SG177533A1 (en) 2009-07-07 2012-02-28 Novartis Ag Conserved escherichia coli immunogens
DK3178490T3 (da) 2009-07-15 2022-06-20 Glaxosmithkline Biologicals Sa RSV F-proteinsammensætninger og fremgangsmåder til fremstilling af disse
CN102770443A (zh) 2009-07-16 2012-11-07 诺华有限公司 脱毒大肠杆菌免疫原
EP2453903B1 (fr) 2009-07-17 2016-08-17 Industry Academic Cooperation Foundation, Hallym University Compositions immunostimulatrices comprenant des oligonucléotides et épitopes encapsulés par liposome
EP2281579A1 (fr) 2009-08-05 2011-02-09 BioNTech AG Composition de vaccin comportant un ADN modifié 5'-Cap
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
US20120190634A1 (en) 2009-08-26 2012-07-26 Rna Inc. Lipoteichoic acid-derived glycolipids, and compositions comprising same
WO2011024072A2 (fr) 2009-08-27 2011-03-03 Novartis Ag Polypeptides hybrides contenant des séquences fhbp à méningocoques
US20120283115A1 (en) 2009-08-31 2012-11-08 Ludwig Institute For Cancer Research Ltd. Seromic analysis of ovarian cancer
US20110110980A1 (en) 2009-09-02 2011-05-12 Wyeth Llc Heterlogous prime-boost immunization regimen
CN102695523A (zh) 2009-09-10 2012-09-26 诺华有限公司 针对呼吸道疾病的组合疫苗
SG179037A1 (en) * 2009-09-10 2012-04-27 Merial Ltd New vaccine formulations comprising saponin-containing adjuvants
WO2011034950A1 (fr) 2009-09-16 2011-03-24 Vaxart, Inc. Stratégie d'immunisation pour empêcher une infection par le h1n1
GB0917457D0 (en) 2009-10-06 2009-11-18 Glaxosmithkline Biolog Sa Method
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
GB0917002D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Improved shigella blebs
CA2779798C (fr) 2009-09-30 2019-03-19 Novartis Ag Conjugaison de polysaccharides capsulaires de staphylococcus aureus de type 5 et de type 8
AU2010302344A1 (en) 2009-09-30 2012-04-26 Novartis Ag Expression of meningococcal fhbp polypeptides
WO2011040978A2 (fr) 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd. Epitopes de ny-eso-1 immunodominants restreints par dr52b du cmh, monomères et multimères du cmh de classe ii et leur utilisation
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
BR112012010531A2 (pt) 2009-10-27 2019-09-24 Novartis Ag "polipeptídeos de modificação meningocócica fhbp"
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
US9487584B2 (en) 2009-11-11 2016-11-08 Ganymed Pharmaceuticals Ag Antibodies specific for claudin 6 (CLDN6)
EP2322555A1 (fr) 2009-11-11 2011-05-18 Ganymed Pharmaceuticals AG Anticorps spécifiques pour claudin 6 (CLDN6)
WO2011067758A2 (fr) 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Fragments immunogènes et multimères pour protéines de streptococcus pneumoniae
WO2011080595A2 (fr) 2009-12-30 2011-07-07 Novartis Ag Immunogènes de polysaccharide conjugués à des protéines porteuses de e. coli
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003920D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
CN102869377A (zh) 2010-03-10 2013-01-09 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
EP2366709A1 (fr) 2010-03-16 2011-09-21 BioNTech AG Vaccination anti-tumeur impliquant une réponse immunitaire humorale contre les protéines endogènes
EP2547695B1 (fr) 2010-03-16 2018-05-09 Biontech Protein Therapeutics GmbH Vaccination anti-tumeur impliquant une réponse immunitaire humorale contre la protéine endogène CLDN18.2
AU2011231574A1 (en) 2010-03-26 2012-10-11 Glaxosmithkline Biologicals S.A. HIV vaccine
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
WO2011127316A1 (fr) 2010-04-07 2011-10-13 Novartis Ag Procédé de génération de pseudo-particules virales de parvovirus b19
EP2558069A1 (fr) 2010-04-13 2013-02-20 Novartis AG Compositions de benzonapthyridine et leurs utilisations
PL3170508T3 (pl) 2010-06-04 2020-04-30 Wyeth Llc Preparaty szczepionek
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
US20130171185A1 (en) 2010-07-06 2013-07-04 Ethan Settembre Norovirus derived immunogenic compositions and methods
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
EP2404936A1 (fr) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Thérapie du cancer utilisant des anticorps in vivo dirigés sur la cible CLDN6
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
EP3213765B1 (fr) 2010-09-20 2019-08-28 BioNTech Cell & Gene Therapies GmbH Récepteurs de lymphocytes t spécifiques aux antigènes et épitopes de lymphocytes t
US9168292B2 (en) 2010-09-27 2015-10-27 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
GB201017519D0 (en) 2010-10-15 2010-12-01 Novartis Vaccines Inst For Global Health S R L Vaccines
US20130216613A1 (en) 2010-10-15 2013-08-22 Guy Jean Marie Fernand Pierre Baudoux Cytomegalovirus gb antigen
GB201101331D0 (en) 2011-01-26 2011-03-09 Glaxosmithkline Biolog Sa Compositions and uses
WO2012057904A1 (fr) 2010-10-27 2012-05-03 Infectious Disease Research Institute Antigènes du mycobacterium tuberculosis et leurs combinaisons présentant une séroréactivité élevée
WO2012064659A1 (fr) 2010-11-08 2012-05-18 Infectious Disease Research Institute Vaccins comprenant des polypeptides d'hydrolase nucléosidique et de stérol 24-c-méthyltransférase (smt) non spécifiques destinés à traiter et à diagnostiquer la leishmaniose
WO2012072769A1 (fr) 2010-12-01 2012-06-07 Novartis Ag Epitopes rrgb de pneumocoque et combinaisons de variantes
CN106822882A (zh) 2010-12-14 2017-06-13 葛兰素史密丝克莱恩生物有限公司 分枝杆菌抗原组合物
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
EP2655389A2 (fr) 2010-12-24 2013-10-30 Novartis AG Composés
EP3527224A1 (fr) 2011-01-26 2019-08-21 GlaxoSmithKline Biologicals S.A. Régime d'immunisation contre le vrs
WO2012100302A1 (fr) 2011-01-27 2012-08-02 Gamma Vaccines Pty Limited Vaccins associés
CN103517713A (zh) 2011-02-22 2014-01-15 彼昂德瓦克斯医药有限公司 在改善的季节性和大流行性流感疫苗中的多聚体多表位多肽
WO2012135177A2 (fr) 2011-03-29 2012-10-04 Uab Research Foundation Procédés et compositions permettant d'obtenir une protéine il-10 de cytomégalovirus
GB201106357D0 (en) 2011-04-14 2011-06-01 Pessi Antonello Composition and uses thereof
EA027236B1 (ru) 2011-04-08 2017-07-31 Иммьюн Дизайн Корп. Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
EP3421496A1 (fr) 2011-05-13 2019-01-02 Ganymed Pharmaceuticals GmbH Anticorps pour le traitement du cancer exprimant du claudin 6
PT2707385T (pt) 2011-05-13 2017-12-19 Glaxosmithkline Biologicals Sa Antigénios de f de rsv pré-fusão
US20140072622A1 (en) 2011-05-17 2014-03-13 Glaxosmithkline Biologicals S.A. Vaccine against streptococcus pneumoniae
KR101949186B1 (ko) 2011-05-19 2019-02-18 도레이 카부시키가이샤 면역 유도제
AU2012256756B2 (en) 2011-05-19 2017-06-08 Toray Industries, Inc. Immunity induction agent
WO2012159643A1 (fr) 2011-05-24 2012-11-29 Biontech Ag Vaccins individualisés pour le cancer
RS59369B1 (sr) 2011-05-24 2019-11-29 Biontech Rna Pharmaceuticals Gmbh Individualizovane vakcine protiv kancera
CN105999250B (zh) 2011-05-24 2020-03-10 生物技术Rna制药有限公司 用于癌症的个体化疫苗
CA2838188C (fr) 2011-06-04 2017-04-18 Rochester General Hospital Research Institute Compositions et procedes associes a la proteine p6 de l'haemophilus influenzae
US20150030586A1 (en) 2011-06-21 2015-01-29 Sarah Ellen Warren Compositions and methods for the therapy and diagnosis of cancer
CA2841047A1 (fr) 2011-07-06 2013-01-10 Novartis Ag Compositions immunogenes et leurs utilisations
EP3854413A1 (fr) 2011-07-06 2021-07-28 GlaxoSmithKline Biologicals SA Compositions de combinaisons immunogènes et utilisations de celles-ci
WO2013009564A1 (fr) 2011-07-08 2013-01-17 Novartis Ag Procédé de ligature de la tyrosine
EP2736921B1 (fr) 2011-07-25 2018-06-27 GlaxoSmithKline Biologicals SA Compositions et procédés d'évaluation de l'immunogénicité fonctionnelle de vaccins contre un parvovirus
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
GB201114919D0 (en) 2011-08-30 2011-10-12 Glaxosmithkline Biolog Sa Method
WO2013038375A2 (fr) 2011-09-14 2013-03-21 Novartis Ag Procédés de production de glycoconjugués de saccharide-protéine
EP2758432B1 (fr) 2011-09-16 2019-03-06 UCB Biopharma SPRL Anticorps neutralisants contre les toxines principales tcda et tcdb de clostridium difficile
AU2012335208B2 (en) 2011-11-07 2017-08-31 Glaxosmithkline Biologicals S.A. Carrier molecule comprising a spr0096 and a spr2021 antigen
EP2780034A1 (fr) 2011-11-14 2014-09-24 Crucell Holland B.V. Immunisation primovaccination-rappel hétérologue à l'aide de vaccins à base du virus de la rougeole
CN108864291A (zh) 2011-11-23 2018-11-23 拜奥文斯瑞有限公司 重组蛋白及其治疗用途
EP2785683B1 (fr) 2011-11-30 2020-02-05 Ludwig Institute for Cancer Research Ltd. Modulateurs de cellule inkt et leurs procédés d'utilisation
US9089574B2 (en) 2011-11-30 2015-07-28 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
GB201120860D0 (en) 2011-12-05 2012-01-18 Cambridge Entpr Ltd Cancer immunotherapy
WO2013108272A2 (fr) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Vaccin antipaludique ciblant le stade sanguin
ES2729967T3 (es) 2012-02-07 2019-11-07 Infectious Disease Res Inst Formulaciones de adyuvante mejoradas que comprenden agonistas de TLR4 y métodos para usar las mismas
US20130236484A1 (en) 2012-03-08 2013-09-12 Detectogen Inc. Leishmaniasis antigen detection assays and vaccines
EP2833900B1 (fr) 2012-04-01 2018-09-19 Technion Research & Development Foundation Limited Peptides d'inducteur de métalloprotéinase de matrice extracellulaire (emmprin) et anticorps de liaison
WO2013167153A1 (fr) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Anticorps utiles dans le diagnostic du cancer
EP3388835B1 (fr) 2012-05-16 2020-04-01 Immune Design Corp. Vaccins contre le hsv-2
JP2015518845A (ja) 2012-05-22 2015-07-06 ノバルティス アーゲー 髄膜炎菌血清群ｘコンジュゲート
EP2666785A1 (fr) 2012-05-23 2013-11-27 Affiris AG Vaccins basés sur la protéine complément C5a
EP2869842A1 (fr) 2012-07-06 2015-05-13 Novartis AG Compositions immunogéniques et leurs utilisations
GB201213364D0 (en) 2012-07-27 2012-09-12 Glaxosmithkline Biolog Sa Purification process
EP4299138A2 (fr) 2012-08-03 2024-01-03 Access to Advanced Health Institute Compositions et méthodes de traitement d'une infection active par le bacille de koch
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
CA2879939A1 (fr) 2012-08-06 2014-02-13 Glaxosmithkline Biologicals S.A. Procede pour eliciter une reponse immunitaire contre le vrs et b. pertussis chez les nourrissons
EP2703483A1 (fr) 2012-08-29 2014-03-05 Affiris AG Vaccin à base de PCSK9
WO2014043189A1 (fr) 2012-09-14 2014-03-20 The Regents Of The University Of Colorado, A Body Corporate Virus de l'herpès déficients pour la réplication conditionnelle et leur utilisation dans des vaccins
MX363529B (es) 2012-09-18 2019-03-27 Novartis Ag Vesículas de membrana externa.
EA201590427A1 (ru) 2012-10-02 2015-09-30 Глаксосмитклайн Байолоджикалс С.А. Нелинейные сахаридные конъюгаты
US9855324B2 (en) 2012-10-03 2018-01-02 Glaxosmithkline Biologicals Sa Immunogenic compositions
PL2912186T3 (pl) 2012-10-24 2021-06-14 Platelet Targeted Therapeutics Llc Leczenie ukierunkowane na płytki krwi
WO2014074785A1 (fr) 2012-11-08 2014-05-15 Ludwig Institute For Cancer Research Ltd. Procédés de prédiction de l'issue et du traitement du cancer du sein
WO2014082729A1 (fr) 2012-11-28 2014-06-05 Biontech Ag Vaccins individualisés contre le cancer
ES2826555T3 (es) 2012-11-30 2021-05-18 Glaxosmithkline Biologicals Sa Antígenos de Pseudomonas y combinación de antígenos
CN104884081A (zh) 2012-12-05 2015-09-02 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
UY34506A (es) 2012-12-10 2014-06-30 Fernando Amaury Ferreira Chiesa Adyuvante de vacunación, preparación y vacunas que lo contienen
JP6873530B2 (ja) 2013-03-15 2021-05-19 イン3バイオ・リミテッドIn3Bio Ltd. 自己組織化合成タンパク質（Ｓｅｌｆ−Ａｓｓｅｍｂｌｉｎｇ Ｓｙｎｔｈｅｔｉｃ Ｐｒｏｔｅｉｎｓ）
BE1022174B1 (fr) 2013-03-15 2016-02-24 Glaxosmithkline Biologicals S.A. Vaccin
BR112015024860B1 (pt) 2013-03-28 2023-11-07 Access To Advanced Health Institute Polipeptídeo de fusão, polinucleotídeo isolado, composição compreendendo dito polipeptídeo, uso da dita composição para estimular uma resposta imune contra leishmania e método in vitro e kit de diagnóstico para detectar infecção por leishmania em uma amostra biológica
CN105209047B (zh) 2013-04-18 2020-08-18 免疫设计股份有限公司 用于癌症治疗的gla单一疗法
WO2014180490A1 (fr) 2013-05-10 2014-11-13 Biontech Ag Prédiction de l'immunogénicité d'épitopes de lymphocytes t
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
CN105473603B (zh) 2013-06-26 2019-10-25 北卡罗来纳-查佩尔山大学 用于登革病毒疫苗的方法与组合物
EP3027203B1 (fr) 2013-07-30 2020-07-29 BioNTech SE Antigenes de tumeur pour determiner la therapie du cancer
WO2015014376A1 (fr) 2013-07-31 2015-02-05 Biontech Ag Diagnostic et thérapie du cancer impliquant des cellules souches cancéreuses
KR20160040290A (ko) 2013-08-05 2016-04-12 글락소스미스클라인 바이오로지칼즈 에스.에이. 조합 면역원성 조성물
KR101977449B1 (ko) 2013-11-01 2019-05-10 유니버시티에트 이 오슬로 알부민 변이체 및 이의 용도
EP2870974A1 (fr) 2013-11-08 2015-05-13 Novartis AG Vaccins conjugués de salmonelle
EP3068426B1 (fr) 2013-11-13 2020-02-12 University Of Oslo Vésicules de membrane externe et utilisation associées
US11452767B2 (en) 2013-11-15 2022-09-27 Oslo Universitetssykehus Hf CTL peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
WO2015077434A2 (fr) 2013-11-20 2015-05-28 La Jolla Institute For Allergy And Immunology Immunogènes contre plusieurs pollens et procédés et utilisations pour moduler la réponse immunitaire
WO2015077442A2 (fr) 2013-11-20 2015-05-28 La Jolla Institute For Allergy And Immunology Immunogènes de pollen de graminée ainsi que procédés et utilisations pour la modulation de la réponse immunitaire
WO2015092710A1 (fr) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Administration simultanée controlatérale de vaccins
US11801223B2 (en) 2013-12-31 2023-10-31 Access To Advanced Health Institute Single vial vaccine formulations
US20170224805A1 (en) 2014-02-20 2017-08-10 Vaxart, Inc. Formulations for small intestinal delivery
TW201620927A (zh) 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Ｕｓｐａ２蛋白質構築體及其用途
WO2015131053A1 (fr) 2014-02-28 2015-09-03 Alk-Abelló A/S Polypeptides dérivés de phl p, procédés et utilisations de ces derniers pour moduler une réponse immunitaire
JP6608422B2 (ja) * 2014-03-25 2019-11-20 ザ ガバメント オブ ザ ユナイテッド ステイツ，アズ リプリゼンティッド バイ ザ セクレタリー オブ ジ アーミー モノホスホリルリピッドａ（ｍｐｌａ）含有リポソーム組成物およびサポニンを含む非毒性アジュバント製剤
LT3122378T (lt) 2014-03-26 2020-02-10 Glaxosmithkline Biologicals S.A. Mutantų stafilokokiniai antigenai
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
JP6664338B2 (ja) 2014-06-13 2020-03-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組合せ物
SI3160500T1 (sl) 2014-06-25 2019-11-29 Glaxosmithkline Biologicals Sa Imunogeni sestavek proti Clostridium difficile
TW201623329A (zh) 2014-06-30 2016-07-01 亞佛瑞司股份有限公司 針對骨調素截斷變異體的疫苗及單株抗體暨其用途
US10759836B2 (en) 2014-07-18 2020-09-01 University Of Washington Cancer vaccine compositions and methods of use thereof
AR101256A1 (es) 2014-07-21 2016-12-07 Sanofi Pasteur Composición vacunal que comprende ipv y ciclodextrinas
ES2924988T3 (es) 2014-10-10 2022-10-13 Univ Michigan Regents Composiciones con nanoemulsiones para prevenir, inhibir o eliminar una enfermedad alérgica e inflamatoria
WO2016062323A1 (fr) 2014-10-20 2016-04-28 Biontech Ag Methodes et compositions de diagnostic et de traitement du cancer
MX2017005524A (es) 2014-11-02 2018-01-26 Univ North Carolina Chapel Hill Metodos y composiciones para el virus del dengue recombinante para el desarrollo de vacunas y de diagnostico.
EP3229833A1 (fr) 2014-12-10 2017-10-18 GlaxoSmithKline Biologicals SA Procédé de traitement
WO2016128060A1 (fr) 2015-02-12 2016-08-18 Biontech Ag Prédiction des épitopes de lymphocytes t utiles pour la vaccination
WO2016134300A1 (fr) 2015-02-20 2016-08-25 Board Of Regents, The University Of Texas System Méthodes et compositions permettant d'utiliser la chlamydia atténuée en tant que vaccin et vecteur
CA2977493C (fr) 2015-03-03 2023-05-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Plateforme d'affichage provenant de proteines d'enveloppe de spores bacteriennes
CN107530416A (zh) 2015-03-05 2018-01-02 西北大学 非神经侵染的病毒及其用途
JP2018511655A (ja) 2015-03-20 2018-04-26 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ボルデテラ属に対するワクチン接種における使用のための免疫原性組成物
AU2016236770B2 (en) 2015-03-26 2022-03-10 Gpn Vaccines Pty Ltd Streptococcal vaccine
RU2017140856A (ru) 2015-05-26 2019-06-26 Огайо Стейт Инновейшн Фаундейшн Стратегия вакцинации против вируса свиного гриппа вакциной на основе наночастиц
CN118045170A (zh) 2015-06-12 2024-05-17 瓦克萨特公司 用于rsv和诺如病毒抗原的小肠递送的制剂
EP3138579A1 (fr) 2015-09-05 2017-03-08 Biomay Ag Protéine de fusion pour son utilisation dans le traitement d'une infection par le virus de l'hépatite b
MX2018004802A (es) * 2015-10-19 2018-09-06 Cadila Healthcare Ltd Nuevo adyuvante y composición de vacuna que contiene el mismo.
GB201518668D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
GB201522132D0 (en) * 2015-12-15 2016-01-27 Glaxosmithkline Biolog Sa Vaccine
BE1024160B9 (fr) 2015-12-22 2017-12-06 Glaxosmithkline Biologicals Sa Formulation immunogène
GB201603625D0 (en) 2016-03-02 2016-04-13 Glaxosmithkline Biolog Sa Novel influenza antigens
CA3017356A1 (fr) 2016-03-10 2017-09-14 Aperisys, Inc. Proteines de fusion se liant a un antigene et ayant des domaines hsp70 modifies
WO2017158421A1 (fr) 2016-03-14 2017-09-21 University Of Oslo Immunoglobulines anti-virales synthétiques
JP7155008B2 (ja) 2016-03-14 2022-10-18 ウニヴァーシテテット イ オスロ 変化されたＦｃＲｎを有する改変された免疫グロブリン
WO2017170365A1 (fr) 2016-03-28 2017-10-05 東レ株式会社 Agent induisant l'immunité
WO2017167768A1 (fr) 2016-03-28 2017-10-05 Glaxosmithkline Biologicals S.A. Nouvelle composition vaccinale
WO2017201390A1 (fr) 2016-05-19 2017-11-23 The Regents Of The University Of Michigan Nouvelles compositions adjuvantes
MX2018014270A (es) 2016-05-21 2019-02-14 Infectious Disease Res Inst Composiciones y metodos para tratar la tuberculosis secundaria e infecciones po micobacteria no tuberculosa.
US11780924B2 (en) 2016-06-21 2023-10-10 University Of Oslo HLA binding vaccine moieties and uses thereof
US20190189241A1 (en) 2016-07-20 2019-06-20 Biontech Rna Pharmaceuticals Gmbh Selecting Neoepitopes as Disease-Specific Targets for Therapy with Enhanced Efficacy
MX2019002178A (es) 2016-08-23 2019-09-18 Glaxosmithkline Biologicals Sa Peptidos de fusion con antigenos enlazados a fragmentos cortos de cadena invariante (cd74).
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
US11801290B2 (en) 2016-09-16 2023-10-31 Access To Advanced Health Institute Vaccines comprising Mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy
EP3295956A1 (fr) 2016-09-20 2018-03-21 Biomay Ag Construction de polypeptide comprenant des fragments d'allergenes
EP3518966A1 (fr) 2016-09-29 2019-08-07 GlaxoSmithKline Biologicals S.A. Compositions et méthodes de traitement d'une infection par hpv persistante
GB201616904D0 (en) 2016-10-05 2016-11-16 Glaxosmithkline Biologicals Sa Vaccine
WO2018077385A1 (fr) 2016-10-25 2018-05-03 Biontech Rna Pharmaceuticals Gmbh Détermination de doses d'agents immunothérapeutiques
WO2018096396A1 (fr) 2016-11-22 2018-05-31 University Of Oslo Variants d'albumine et leurs utilisations
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
MX2019006349A (es) 2016-12-16 2019-08-22 Inst Res Biomedicine Proteinas recombinantes rsv f de prefusion nuevas y usos de las mismas.
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
WO2018178265A1 (fr) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Composition immunogène, utilisation et procédé de traitement
CN110662557A (zh) 2017-03-31 2020-01-07 葛兰素史克知识产权开发有限公司 免疫原性组合物、用途和治疗方法
US20200093909A1 (en) 2017-04-19 2020-03-26 Institute For Research In Biomedicine Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to
SG10202108075YA (en) * 2017-04-25 2021-09-29 Adjuvance Technologies Inc Triterpene saponin analogues
WO2018198085A1 (fr) 2017-04-28 2018-11-01 Glaxosmithkline Biologicals Sa Vaccination
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
IE87414B1 (en) * 2017-05-30 2023-07-19 Glaxosmithkline Biologicals Sa Novel methods for manufacturing an adjuvant
CN107375921B (zh) * 2017-06-12 2019-10-29 商丘美兰生物工程有限公司 一种甘草皂苷脂质体免疫佐剂及其制备方法
CA3066020A1 (fr) 2017-06-16 2018-12-20 Glaxosmithkline Biologicals Sa Methode de traitement
IL300235A (en) 2017-07-18 2023-03-01 In3Bio Ltd Synthetic proteins and their therapeutic uses
EP3641808A1 (fr) 2017-08-14 2020-04-29 GlaxoSmithKline Biologicals S.A. Procédés d'amplification des réponses immunitaires
WO2019035963A1 (fr) 2017-08-16 2019-02-21 Ohio State Innovation Foundation Compositions à nanoparticules pour vaccins contre les salmonelles
US12005112B2 (en) 2017-09-07 2024-06-11 University Of Oslo Vaccine molecules
WO2019048928A1 (fr) 2017-09-07 2019-03-14 University Of Oslo Molécules de vaccin
EP3678695A1 (fr) 2017-09-08 2020-07-15 Infectious Disease Research Institute Formulations liposomales comprenant de la saponine et procédés d'utilisation
WO2019079594A1 (fr) 2017-10-18 2019-04-25 The University Of North Carolina At Chapel Hill Méthodes et compositions pour des vaccins contre les novovirus et le diqagnostic des novovirus
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
KR102286397B1 (ko) 2018-02-02 2021-08-05 주식회사 에스엘백시젠 신규 백신 면역보조제
JP7416705B2 (ja) 2018-03-15 2024-01-17 バイオエヌテック エスエー ５’キャップトリヌクレオチドまたはより高級のオリゴヌクレオチド化合物、ならびにｒｎａの安定化、タンパク質の発現および治療法におけるそれらの使用
EP3569612A1 (fr) 2018-05-18 2019-11-20 Biomay Ag Traitement et prévention d'allergies aux acariens
CN112638936A (zh) 2018-06-12 2021-04-09 葛兰素史密丝克莱恩生物有限公司 腺病毒多核苷酸和多肽
EP3581201A1 (fr) 2018-06-15 2019-12-18 GlaxoSmithKline Biologicals S.A. Escherichia coli o157:h7 polypeptides et leurs utilisations
WO2020030572A1 (fr) 2018-08-07 2020-02-13 Glaxosmithkline Biologicals Sa Processus et vaccins
US20210220462A1 (en) 2018-08-23 2021-07-22 Glaxosmithkline Biologicals Sa Immunogenic proteins and compositions
WO2020051766A1 (fr) 2018-09-11 2020-03-19 上海市公共卫生临床中心 Immunogène pour vaccin à large spectre contre la grippe, et application de celui-ci
WO2020055503A1 (fr) 2018-09-14 2020-03-19 Massachusetts Institute Of Technology Adjuvant vaccinal à base de nanoparticules, et méthodes d'utilisation associées
EP3890775A1 (fr) 2018-12-06 2021-10-13 GlaxoSmithKline Biologicals S.A. Compositions immunogènes
EP3897846A1 (fr) 2018-12-21 2021-10-27 GlaxoSmithKline Biologicals SA Méthodes d'induction d'une réponse immunitaire
US11419932B2 (en) 2019-01-24 2022-08-23 Massachusetts Institute Of Technology Nucleic acid nanostructure platform for antigen presentation and vaccine formulations formed therefrom
GB201901608D0 (en) 2019-02-06 2019-03-27 Vib Vzw Vaccine adjuvant conjugates
CN113573730A (zh) 2019-03-05 2021-10-29 葛兰素史密斯克莱生物公司 乙型肝炎免疫方案和组合物
CA3141577A1 (fr) 2019-05-25 2020-12-03 Infectious Disease Research Institute Composition et procede de sechage par atomisation d'une emulsion de vaccin et d'adjuvant
BR112021026132A2 (pt) 2019-06-25 2022-02-08 In3Bio Ltd Proteínas sintéticas quiméricas estabilizadas e usos terapêuticos das mesmas
JP2022542032A (ja) 2019-07-21 2022-09-29 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 治療用ウイルスワクチン
EP4004018A1 (fr) 2019-07-24 2022-06-01 GlaxoSmithKline Biologicals SA Protéines de cytomégalovirus humain modifiées
EP4010014A1 (fr) 2019-08-05 2022-06-15 GlaxoSmithKline Biologicals S.A. Composition immunogène
EP3777884A1 (fr) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Composition immunogène
EP3799884A1 (fr) 2019-10-01 2021-04-07 GlaxoSmithKline Biologicals S.A. Compositions immunogènes
KR20220107166A (ko) 2019-10-02 2022-08-02 얀센 백신스 앤드 프리벤션 비.브이. 스타필로코커스 펩티드 및 사용 방법
EP4058581A1 (fr) 2019-11-15 2022-09-21 Infectious Disease Research Institute Agoniste de rig-i et formulation d'adjuvant pour le traitement de tumeurs
EP4077356A1 (fr) 2019-12-19 2022-10-26 GlaxoSmithKline Biologicals SA Antigènes de s. aureus et compositions associées
CN115038461A (zh) 2020-01-16 2022-09-09 杨森制药公司 FimH突变体、其组合物及其用途
EP4114848A4 (fr) 2020-02-26 2024-04-03 Versitech Limited Vaccins à base de pd-1 dirigés contre une infection à coronavirus
WO2021245611A1 (fr) 2020-06-05 2021-12-09 Glaxosmithkline Biologicals Sa Protéines modifiées de spicule de coronavirus bêta
WO2022029024A1 (fr) 2020-08-03 2022-02-10 Glaxosmithkline Biologicals Sa PROTÉINE FUSOBACTERIUM ADHÉSINE A (FadA) DE FUSOBACTERIUM NUCLEATUM TRONQUÉE ET COMPOSITIONS IMMUNOGÈNES À BASE DE CELLE-CI
US11225508B1 (en) 2020-09-23 2022-01-18 The University Of North Carolina At Chapel Hill Mouse-adapted SARS-CoV-2 viruses and methods of use thereof
US20230416309A1 (en) 2020-10-23 2023-12-28 Jiangsu Provincial Center For Disease Control And Prevention (Public Health Research Institute Of Ji Fusion protein and application thereof
KR20230097028A (ko) 2020-10-28 2023-06-30 사노피 파스퇴르 Tlr4 효현제를 함유하는 리포좀, 이의 제조 및 용도
MX2023006320A (es) 2020-12-02 2023-06-14 Glaxosmithkline Biologicals Sa Cadena donante complementada fimh.
WO2022153166A1 (fr) 2021-01-12 2022-07-21 Janssen Pharmaceuticals, Inc. Mutants fimh, compositions à base de celui-ci et leur utilisation
EP4032547A1 (fr) 2021-01-20 2022-07-27 GlaxoSmithKline Biologicals S.A. Fragments dérivés du hsv 1 fce pour le traitement du hsv
EP4294433A1 (fr) 2021-02-22 2023-12-27 GlaxoSmithKline Biologicals SA Composition immunogène, utilisation et procédés
WO2022192038A1 (fr) 2021-03-12 2022-09-15 Northwestern University Vaccins antiviraux utilisant des acides nucléiques sphériques
EP4313138A1 (fr) 2021-03-30 2024-02-07 Viravaxx AG Vaccin sous-unitaire contre le sars-cov-2
EP4313132A1 (fr) 2021-03-31 2024-02-07 Vib Vzw Compositions de vaccin pour trypanosomatides
CA3215752A1 (fr) 2021-04-01 2022-10-06 Janssen Pharmaceuticals, Inc. Production de bioconjugues d'e. coli o18
WO2023274860A1 (fr) 2021-06-28 2023-01-05 Glaxosmithkline Biologicals Sa Nouveaux antigènes de la grippe
WO2023046898A1 (fr) 2021-09-23 2023-03-30 Viravaxx AG Vaccin contre le virus de l'hépatite b induisant la production d'anticorps neutralisants spécifiques de pres
WO2023079528A1 (fr) 2021-11-05 2023-05-11 King Abdullah University Of Science And Technology Compositions appropriées pour une utilisation dans un procédé pour déclencher une immunité protectrice croisée contre des coronavirus
WO2023079529A1 (fr) 2021-11-05 2023-05-11 King Abdullah University Of Science And Technology Compositions d'immunisation de rappel de protéine de refocalisation et leurs méthodes d'utilisation
WO2023114727A1 (fr) 2021-12-13 2023-06-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Système de vaccin du bactériophage lambda
WO2023114570A1 (fr) 2021-12-19 2023-06-22 Massachusetts Institute Of Technology Compositions et méthodes pour obtenir des réponses durables des centres germinatifs à une sensibilisation active
WO2023144665A1 (fr) 2022-01-28 2023-08-03 Glaxosmithkline Biologicals Sa Protéines de cytomégalovirus humain modifiées
WO2023154960A1 (fr) 2022-02-14 2023-08-17 University Of Georgia Research Foundation, Inc. Compositions de vaccins pan-pneumovirus et leurs méthodes d'utilisation
WO2024116096A1 (fr) 2022-12-01 2024-06-06 Pfizer Inc. Formulations de vaccin pneumococcique conjugué
WO2024130009A1 (fr) 2022-12-14 2024-06-20 Yale University Compositions et leurs procédés d'utilisation pour le traitement de cancers entraînés par un virus

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ230747A (en) * 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
DK0454735T3 (da) * 1989-01-23 1996-10-07 Auspharm Int Ltd Vaccine sammensætning
GB8919819D0 (en) * 1989-09-01 1989-10-18 Coopers Animal Health Complexes having adjuvant activity
NL9002314A (nl) * 1990-10-23 1992-05-18 Nederlanden Staat Immunogene complexen, in het bijzonder iscoms.
ATE188613T1 (de) * 1992-06-25 2000-01-15 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
CA2156525A1 (fr) * 1993-02-19 1994-09-01 Susan Dillon Compositions a base de lipide a monophosphoryle 3-o-desacyle pour des vaccins anti-grippe
HU219056B (hu) * 1993-03-23 2001-02-28 Smithkline Beecham Biologicals Sa 3-O-Dezacilezett monofoszforil-lipid A-t tartalmazó vakcinakészítmény
US5723130A (en) * 1993-05-25 1998-03-03 Hancock; Gerald E. Adjuvants for vaccines against respiratory syncytial virus
AUPM873294A0 (en) * 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
GB9718901D0 (en) † 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine

Also Published As

Publication number Publication date
CN1480214A (zh) 2004-03-10
SK282017B6 (sk) 2001-10-08
DE69605296T2 (de) 2000-05-18
EP0884056A1 (fr) 1998-12-16
HUP9801560A3 (en) 1999-07-28
EP0822831A1 (fr) 1998-02-11
AR001686A1 (es) 1997-11-26
PT955059E (pt) 2007-11-27
EP0955059A3 (fr) 2000-07-12
SA96170297B1 (ar) 2005-11-15
AP9701123A0 (en) 1997-10-31
BR9608199A (pt) 1999-05-18
MA23850A1 (fr) 1996-12-31
HK1025244A1 (en) 2000-11-10
RO119068B1 (ro) 2004-03-30
NO974859L (no) 1997-10-21
TR199701252T1 (xx) 1998-03-21
IL118004A0 (en) 1996-08-04
ES2140076T5 (es) 2007-04-16
SI0955059T1 (sl) 2008-02-29
AU6987398A (en) 1998-07-23
EP0955059A2 (fr) 1999-11-10
MY134811A (en) 2007-12-31
CN1515245A (zh) 2004-07-28
ATE186842T1 (de) 1999-12-15
DK0822831T4 (da) 2006-12-27
AU5334596A (en) 1996-11-18
EA199700272A1 (ru) 1998-04-30
EP0822831B1 (fr) 1999-11-24
DK0955059T3 (da) 2007-12-17
NO974859D0 (no) 1997-10-21
GR3031912T3 (en) 2000-02-29
CN1182370A (zh) 1998-05-20
KR100463372B1 (ko) 2005-02-28
BR9608199B1 (pt) 2009-05-05
EA000839B1 (ru) 2000-04-24
DE69605296T3 (de) 2007-02-15
CA2217178C (fr) 2009-09-29
AU693022B2 (en) 1998-06-18
CN1289065C (zh) 2006-12-13
CZ337997A3 (cs) 1998-03-18
DK0822831T3 (da) 2000-05-01
IL118004A (en) 1999-11-30
BG101995A (en) 1998-11-30
AU699213B2 (en) 1998-11-26
JP3901731B2 (ja) 2007-04-04
TW515715B (en) 2003-01-01
HU227944B1 (en) 2012-06-28
PL184061B1 (pl) 2002-08-30
DE69637254D1 (de) 2007-10-31
ATE373487T1 (de) 2007-10-15
NZ305365A (en) 1999-05-28
CN1248737C (zh) 2006-04-05
WO1996033739A1 (fr) 1996-10-31
OA10629A (en) 2002-09-16
EP0822831B2 (fr) 2006-08-23
DE69605296D1 (de) 1999-12-30
CZ296216B6 (cs) 2006-02-15
HUP9801560A1 (hu) 1998-10-28
BG63491B1 (bg) 2002-03-29
PL322968A1 (en) 1998-03-02
HK1009086A1 (en) 1999-05-28
NO322190B1 (no) 2006-08-28
ES2140076T3 (es) 2000-02-16
DE69637254T2 (de) 2008-06-19
JPH11504020A (ja) 1999-04-06
KR19990008003A (ko) 1999-01-25
UA56132C2 (uk) 2003-05-15
MX9708226A (es) 1998-06-30
CY2588B2 (en) 2009-11-04
SI0822831T2 (sl) 2006-12-31
SK144297A3 (en) 1998-05-06
ES2293708T3 (es) 2008-03-16
AP771A (en) 1999-10-07
SI0822831T1 (en) 2000-02-29
EP0955059B1 (fr) 2007-09-19
CA2217178A1 (fr) 1996-10-31
CN1111071C (zh) 2003-06-11

Similar Documents

Publication Publication Date Title
DZ2026A1 (fr) Compositions vaccinantes.
DZ2055A1 (fr) Compositions vaccinantes.
DZ1763A1 (fr) Composition vaccinantes.
DE69636353D1 (de) Datenübetragungsvorrichtung.
NL1004863A1 (nl) 5-Amino-4-ethylsulfinyl-1-arylpyrazolen.
IS1903B (is) 2-methýl-thíenó-bensódíasepín, samsetning til inntöku
TR199501724A2 (tr) Sizdirmazlik saglayici düzen.
FI950715A0 (fi) Ytmikromekanisk, symmetrisk tryckskillnadsgivare
NL1000095C2 (nl) Rolhor.
DK0874814T3 (da) 25-hydroxy-16-en-26,27-bishomo-cholecalciferoler
TR199601012A2 (tr) Sampuan terkibi.
ES1032571Y (es) Gafa,
ES1032948Y (es) Aplique.
ES1032568Y (es) Protector-precinto.
ES1032636Y (es) Osario.
ES1030124Y (es) Bloc-pizarra.
ES1029950Y (es) Interruptor-conmutador.
ES1030262Y (es) Porta-objetos.
ES1030500Y (es) Braga-compresa monouso.
IT235624Y1 (it) Portatenda.
IT1282308B1 (it) Portaguinzagli.
IT239292Y1 (it) Volter.
ES1030760Y (es) Tocado-postizo.
ES1031132Y (es) Prensa-latas.
ES1033612Y (es) Octocarton.